Medicare policy change could increase inequity in heart transplant access, study finds

Patients seen at transplant centers had almost 80% higher odds to receive “bridge-to-transplant” designation

8:49 AM

Author | Johanna Younghans Baker

VAD heart device cooler red and teal
Jacob Dwyer, Michigan Medicine

A change to Medicare policy surrounding heart transplant may lead to increased inequities in access to transplant for patients with heart failure, a Michigan Medicine study finds.

When a patient has severe heart failure, both a heart transplant and left ventricular assist device, which is implanted to assist the heart in improving blood circulation throughout the body, can be lifesaving. While LVADs continue to improve, heart transplant remains the gold standard therapy for end-stage heart failure.

In the United States, there are many health centers that implant LVADs but don’t perform transplants. Recognizing improved outcomes for patients with LVADs, the Centers for Medicare & Medicaid Services revised its national coverage decision in a manner expected to increase access to the life-altering devices. Starting in 2020, patients receiving an LVAD at a center not capable of transplant no longer needed permission from a Medicare-approved transplant center authorizing it if the patient was a transplant candidate.

SEE ALSO: Her heart stopped more than 25 times. ECMO saved her life

While the relaxed requirements have the potential to increase access to LVADs for patients with heart failure, a study published in JAMA Network Open finds that patients receiving LVADs at transplant-capable centers had 79% higher odds to receive a bridge-to-transplant designation than patients treated at LVAD-only centers.

This Medicare policy change may have the unintended consequence of further increased inequities in access to heart transplant for patients who are treated at centers that don’t perform transplant, said senior author Thomas Cascino, M.D., a cardiologist at the University of Michigan Health Frankel Cardiovascular Center and a clinical instructor in the Division of Cardiovascular Disease at U-M Medical School.

“Our study shows that this disparity existed before the policy change, and we think it will likely grow larger now that there is less collaboration,” Cascino said. “Being cared for at a center that does not perform heart transplant should not result in a lesser chance to receive a heart transplant.”

SEE ALSO: Life with a Ventricular Assist Device: A Nurse Answers Common Questions

Over two years, 25.6% of patients who received an LVAD at a transplant center eventually received a heart transplant, compared to just under 12% at LVAD-only centers.

An additional change impacting the disparity, Cascino notes, is a 2018 policy change made by the United Network for Organ Sharing that, while made with the goal prioritizing those at highest risk of death on the waiting ling, made it much less likely for patients receiving LVADs to receive a heart transplant unless urgent complications arose.

“The heart allocation system change has created a reality in which durable LVADs are much less likely to be a bridge to the best therapy — transplant — in the current system,” he said. “This puts the onus on the transplant community to select appropriate LVAD and transplant candidates during the initial evaluation. We need a system in which any patient can walk into the same hospital and get the right therapy for them.”

Live your healthiest life: Get tips from top experts weekly. Subscribe to the Michigan Health blog newsletter

Headlines from the frontlines: The power of scientific discovery harnessed and delivered to your inbox every week. Subscribe to the Michigan Health Lab blog newsletter

Like Podcasts? Add the Michigan Medicine News Break on Spotify, Apple Podcasts or anywhere you listen to podcasts.

Additional authors include Jeffrey S. McCullough, Ph.D., Xiaoting Wu, Ph.D., Michael J. Pienta, M.D., M.Sc., James W. Stewart II, M.D., Robert B. Hawkins, M.D., M.Sc., Alexander A. Brescia, M.D., M.Sc., Ashraf About el ela, M.D., Min Zhand, Ph.D., Pierre-Emmanuel Noly, M.D., Ph.D., Jonathan W. Haft, M.D., Monica Colvin, M.D., Keith D. Aaronson, M.D., M.S., Francis D. Pagani, M.D., Ph.D., Donald S. Likosky, Ph.D., all of University of Michigan, Jennifer A. Cowger, M.D., M.S., Henry Ford Hospital.

This project was supported in part through funding from the University of Michigan Health Department of Cardiac Surgery and by funding from the National Institutes of Health, National Heart, Lung, and Blood Institute.

Paper cited: “Comparison of Evaluations for Heart Transplant Before Durable Left Ventricular Assist Device and Subsequent Receipt of Transplant at Transplant vs Nontransplant Centers,” JAMA Network Open. DOI: 10.1001/jamanetworkopen.2022.40646


More Articles About:

All Research Topics Surgery Types Surgery Pre- and Post-Operative Health Care Quality Health Care Delivery, Policy and Economics Hospitals & Centers Industry DX
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Medicaid magnifying glass
Health Lab

What’s changing in Medicaid and what can you do?

With eligibility rules for people with lower incomes changing in every state, it’s important to stay up to date, seek trustworthy sources and not fall for misinformation
layers of skin pink to yellow
Health Lab

Study outlines a new framework for direct cell reprogramming

In a new paper published in the journal iScience, Lindsey Muir, Ph.D. and her lab at Michigan Medicine propose a framework for direct cell reprogramming.
people crowd aerial network connections
Health Lab

New insight into how lipodystrophy can affect overall health

What is lipodystrophy? Expert insights on partial vs. generalized fat loss, health complications, leptin therapy, and emerging clinical research.
red blood cells going through clear tube red background
Health Lab

FDA-approved drug offers hope for patients with polycythemia vera, a rare bone marrow disorder

FDA-approved rusfertide offers new hope for polycythemia vera patients by reducing phlebotomy dependence, easing symptoms, and improving daily life.
cells close up blue and green background microscope
Health Lab

Engineered nanoparticles sensitize gliomas to radiotherapy

University of Michigan researchers discovered a new pathway that sensitizes mIDH1 gliomas to radiation in human and mouse mIDH1 glioma cells and mouse models, paving the way for phase 1 clinical trials in humans
getty image of a woman bending over in a red seat in pain with green painted background
Health Lab

Who’s at risk for painful periods?

A University of Michigan-led study looked more closely at dysmenorrhea, which is pain that comes with menstruation, in girls before and after their first periods.